Results 281 to 288 of about 77,108 (288)

Recent developments in the medical and surgical treatment of melanoma

Ca-A Cancer Journal for Clinicians, 2014
Jonathan S Zager
exaly  

Ipilimumab

Reactions Weekly, 2022
openaire   +1 more source

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer Cell, 2018
Matthew D Hellmann, Margaret K Callahan, Emiliano Calvo   +2 more
exaly  

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Lancet, The, 2014
Caroline Robert, Antoni Ribas, Omid Hamid   +2 more
exaly  

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Lancet Oncology, The, 2019
Caroline Robert, Antoni Ribas, Ana Arance   +2 more
exaly  

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Lancet Oncology, The, 2014
Howard I Scher, Michael Krainer, Hakim Mahammedi   +2 more
exaly  

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Lancet Oncology, The, 2016
Scott J Antonia, Filippo de Braud, Michael A Morse   +2 more
exaly  

Ipilimumab

Reactions Weekly, 2020
openaire   +1 more source